On Invalid Date, Vertex Pharmaceuticals (NASDAQ: VRTX) reported Q3 2022 earnings per share (EPS) of $3.63, up 10% year over year. Total Vertex Pharmaceuticals earnings for the quarter were $930.50 million. In the same quarter last year, Vertex Pharmaceuticals's earnings per share (EPS) was $3.30.
As of Q1 2023, Vertex Pharmaceuticals's earnings has grown 52.02% year over year. This is 34.14 percentage points higher than the US Biotechnology industry earnings growth rate of 17.88%. Vertex Pharmaceuticals's earnings in the past year totalled $3.27 billion.
What was VRTX's revenue last quarter?
On Invalid Date, Vertex Pharmaceuticals (NASDAQ: VRTX) reported Q3 2022 revenue of $2.33 billion up 17.65% year over year. In the same quarter last year, Vertex Pharmaceuticals's revenue was $1.98 billion.
What was VRTX's revenue growth in the past year?
As of Q1 2023, Vertex Pharmaceuticals's revenue has grown 22.03% year over year. This is 98.33 percentage points lower than the US Biotechnology industry revenue growth rate of 120.36%. Vertex Pharmaceuticals's revenue in the past year totalled $8.70 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.